Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.

@article{Everett2018AntiInflammatoryTW,
  title={Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.},
  author={Brendan M. Everett and Marc Yves Donath and Aruna Das Pradhan and Tom Thuren and Prem S Pais and Jos{\'e} Carlos Nicolau and Robert J Glynn and Peter Libby and Paul M. Ridker},
  journal={Journal of the American College of Cardiology},
  year={2018},
  volume={71 21},
  pages={2392-2401}
}
BACKGROUND Subclinical inflammation mediated in part by interleukin (IL)-1β participates in peripheral insulin resistance and impaired pancreatic insulin secretion. OBJECTIVES The authors tested the hypothesis that the IL-1β inhibitor canakinumab reduces incident diabetes. METHODS The authors randomized 10,061 patients with prior myocardial infarction and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/l to placebo or canakinumab at doses of 50 mg, 150 mg, or 300 mg subcutaneously once… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 42 times over the past 90 days. VIEW TWEETS